The National Phenome Centre, funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR) and led by Imperial College London and King’s College London, was founded to deliver access to a world-class capability in metabolic phenotyping, to benefit the whole UK translational medicine community.
The establishment of the Centre enables us to take advantage of an unprecedented opportunity offered by the legacy of the 2012 Olympics state-of-the-art drug testing/analytical laboratory.
The Centre delivers its world-class molecular-phenotyoing service using a complimentary mix of analytical platforms, that work in concert to provide the greatest coverage. The Centres’ approach combines Nuclear-Magnetic-Resomace (NMR) spectroscopy, and Ultra-Performance-Liquid-Chromotogrphy coupled to Mass Spectrometry (UPLC-MS) to give unparalleled insight into the molecular composition of samples.
In addition to the initial £10m grant, there was also significant contributions of staff, equipment and technical support from major instrument suppliers of both MS (The Waters Corporation) and NMR (Bruker Biospin GmbH) systems.
The companies have worked with the National Phenome Centre to refine the technological platform underpinning its assays, and to establish a major training centre.